Investors
Kadimastem on Tel-Aviv Stock Exchange
For More Investors Info.
Kadimastem Earns FDA IND Approval For its US Phase IIa Clinical Trial with AstroRx® to Treat ALS
March 19, 2023 at 7:43:32 AM
Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx® for ALS
February 19, 2023 at 10:13:44 AM
Kadimastem's Clinical Trial in ALS Patients was Publicized in the Journal of Translational Medicine
February 15, 2023 at 10:16:24 AM
Awarded Patent in Australia for its AstroRx® Technology for the Treatment of ALS and Drug Screening
February 5, 2023 at 8:15:19 AM
Kadimastem Announces it raised appx 7.5 million NIS by rights offering
January 9, 2023 at 2:19:09 PM
Kadimastem and iTolerance’s Proposed Collaboration With Receipt of US $1 Million BIRD Grant
December 20, 2022 at 9:55:35 AM
Kadimastem Receives Approval of Patent registration Used to Develop IsletRx for Diabetes
September 28, 2022 at 6:47:50 AM
Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment
August 9, 2022 at 7:36:45 AM
Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement
June 8, 2022 at 6:24:04 AM
Kadimastem Awarded Patent in Japan for AstroRx® For ALS and Drug Screening
May 30, 2022 at 12:56:40 PM
Kadimastem Expands R&D Program to Include Multiple Sclerosis
May 17, 2022 at 9:00:00 PM
Kadimastem Receives Grant for a Total Budget of $3.1 million from the Israeli Innovation Authority
March 3, 2022 at 1:08:29 PM
Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority
December 13, 2021 at 10:36:37 AM
ILEX Medical to Invest 10 million NIS ($3.2 million)
November 29, 2021 at 12:20:17 PM
We rang the TASE bell today!
November 15, 2021 at 6:28:17 AM
Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement
October 26, 2021 at 5:52:59 AM
Successful Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes
October 12, 2021 at 1:45:54 PM
Patent for Cell Selection of Beta Cells to Treat and Potentially Cure Diabetes was Granted in Japan
July 21, 2021 at 12:46:30 PM
Kadimastem Announces Publication in Frontiers in Endocrinology of a Peer-Reviewed Article
May 11, 2021 at 11:30:15 AM
Kadimastem Raises NIS 22.3 Million ($6.8 Million)
April 26, 2021 at 7:19:04 AM
Kadimastem Granted a Patent in Israel for the Treatment of ALS
March 9, 2021 at 9:00:16 AM
Kadimastem Announces Executive Management Changes
January 31, 2021 at 10:59:20 AM
Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS
December 15, 2020 at 1:56:27 PM
Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in
August 3, 2020 at 7:11:53 AM
Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
July 27, 2020 at 1:25:35 PM
Kadimastem Announces the Completion of Treatment for Cohort B
July 27, 2020 at 1:25:54 PM
Successful Preclinical results of our Cell Therapy Treatment for Insulin-Dependent Diabetes
July 27, 2020 at 1:27:08 PM
Kadimastem to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol
July 27, 2020 at 1:28:11 PM
Kadimastem to Present at the 7th International Stem Cell Meeting, in Tel-Aviv
November 17, 2019 at 2:10:12 PM
Kadimastem Announces Promising Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
July 27, 2020 at 1:30:03 PM
Kadimastem Announces Leadership Changes
May 20, 2019 at 1:09:25 PM
Kadimastem receives Approval from the Ministry of Health of Israel to continue its trial of AstroRX®
April 18, 2019 at 1:45:49 PM
Appointment of a new CFO for Kadimastem
March 3, 2019 at 7:44:59 AM
Kadimastem Announces the Completion of Cell Transplantation of AstroRx® in ALS Patients for Cohort A
February 24, 2019 at 7:48:37 AM
2019 Israel Innovation Authority Budget Approved for Kadimastem: NIS 13.6 M for ALS Project
February 17, 2019 at 8:00:17 AM
Kadimastem to be included in the TASE Indices
November 27, 2018 at 10:46:59 AM
Success for Kadimastem: 97% of Warrants (Series 4) Exercised for NIS 3.6M
November 14, 2018 at 2:48:21 PM
Kadimastem and Defymed Awarded Grant for the Development of a Product for the Treatment of Diabetes
November 12, 2018 at 2:48:44 PM
FDA Granted Kadimastem Orphan Drug Status for AstroRx® for the Treatment of ALS
November 4, 2018 at 2:47:51 PM
Medical Breakthrough on a Global Scale and Significant Achievement for Kadimastem:
October 9, 2018 at 9:47:57 AM
Altshuler Shaham and Company Stakeholders Lead $5.15 Million Investment in Kadimastem
October 2, 2018 at 1:47:28 PM
Kadimastem and The AFDR Selected to Receive a bi-National Grant
July 2, 2018 at 1:47:12 PM
Kadimastem has Upgraded its Manufacturing Site for Treatment of ALS Patients in the Clinical Trial
July 1, 2018 at 1:46:48 PM
Kadimastem was honored with a prize for excellence for the presentation of the company's technology
June 27, 2018 at 1:46:28 PM
Initiation of coverage report on Kadimastem by global research firm Frost & Sullivan:
January 7, 2019 at 8:15:36 AM
Scientific Article by Kadimastem: Cell-Based Treatment for ALS was Published
June 6, 2018 at 7:21:11 AM
Successful Public Offering for Kadimastem
May 15, 2018 at 7:45:40 AM
Kadimastem Announces the Enrollment of the First Patient for Its Clinical Trial in ALS Patients
April 26, 2018 at 7:47:21 AM
Kadimastem Collaborates with French SME Defymed to Validate a Combined Solution for Type 1 Diabetes
April 21, 2018 at 9:00:00 PM
Successful Rights Offering for Kadimastem; Raised NIS 5.1M
November 13, 2014 at 2:45:07 PM